| "Fifty-three patients with systemic AL amyloidosis (those with malignancies were excluded) were treated in our hospital with HDM (15 patients), melphalan + prednisolone (MP) (17 patients), vincristine + adriamycin + dexamethasone (VAD) (11 patients), or supportive treatment (no chemotherapy, 10 patients)." | ( Hasegawa, E; Hayami, N; Hiramatsu, R; Hoshino, J; Sawa, N; Sumida, K; Suwabe, T; Takaichi, K; Takemoto, F; Taniguchi, S; Ubara, Y; Yamanouchi, M, 2011) |
| "To investigate the treatment of primary amyloidosis with high-dose melphalan and autologous hematopoietic stem cell transplantation to further examine the survival, hematologic response, and improvement of amyloid-related organ dysfunction." | ( Cen, XN; Dong, YJ; Li, Y; Liang, ZY; Liu, W; Ou, JP; Qiu, ZX; Ren, HY; Sun, YH; Wang, LH; Wang, MJ; Wang, WS; Xu, WL; Yin, Y, 2012) |
| "Treatment of primary amyloidosis with high-dose melphalan followed by autologous peripheral blood stem cell transplantation produced high efficacy." | ( Cen, XN; Dong, YJ; Li, Y; Liang, ZY; Liu, W; Ou, JP; Qiu, ZX; Ren, HY; Sun, YH; Wang, LH; Wang, MJ; Wang, WS; Xu, WL; Yin, Y, 2012) |
| "Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed." | ( Adam, Z; Cermáková, Z; Král, Z; Krejčí, M; Pour, L; Sčudla, V, 2013) |
| "Outcome and organ function of stage III AL amyloidosis without very elevated NT-proBNP and low SBP is improved by a very good hematologic response to chemotherapy." | ( Dimopoulos, MA; Foard, D; Foli, A; Gillmore, JD; Hawkins, PN; Hegenbart, U; Kastritis, E; Lane, T; Merlini, G; Milani, P; Palladini, G; Rannigan, L; Schonland, SO; Wechalekar, AD, 2013) |
| "Ten patients with primary systemic AL amyloidosis treated at our institute were evaluated." | ( Aoki, Y; Hayashi, T; Igarashi, T; Ikeda, H; Ishida, T; Maruyama, Y; Nojima, M; Shinomura, Y, 2014) |
| "A 77-year-old Korean man diagnosed with primary amyloidosis was started on melphalan/dexamethasone combination therapy." | ( Choi, BS; Chung, CH; Kim, J; Moon, DS; Moon, WR; Park, SG; Yoon, YM, 2015) |
| "The patients were newly diagnosed with AL amyloidosis with renal (100%), cardiac (72%), hepatic (19%) or nervous system (10%) involvement and underwent a median of 2 (1-6) cycles of BD treatment." | ( Chen, W; Huang, X; Liu, Z; Ren, G; Wang, Q, 2016) |
| "Patients with AL amyloidosis treated with HDM/SCT between 2011 and 2014 with severe hypoalbuminemia (SH), defined as serum albumin ⩽2 g/dL were studied retrospectively." | ( Brauneis, D; Lee, SY; Meehan, RS; Quillen, K; Sanchorawala, V; Seldin, DC; Shelton, A; Sloan, JM, 2016) |
| "Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome." | ( Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F, 2018) |
| "In conclusion, GI perforation in AL amyloidosis is rare and mostly reported after treatment initiation." | ( Avivi, I; Cohen, Y; Duek, A; Gatt, ME; Leiba, M; Shaulov, A, 2018) |
| "Compared with AL amyloidosis, patients with AH amyloidosis exhibit a better prognosis and they may not need an aggressive treatment." | ( Ichimata, S; Kanno, H; Katoh, N; Kobayashi, M; Shimojo, H; Yazaki, M, 2018) |
| "All patients with AL amyloidosis treated with pomalidomide between 2009 and 2017 were included." | ( Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C, 2018) |
| "We report a rare case of AL amyloidosis coincidence with psoriasis treated by ASCT." | ( Chen, W; Huang, X; Ren, G; Zuo, K, 2018) |
| "In appropriately selected patients with AL amyloidosis, autologous stem cell transplant (ASCT) is an established treatment modality with excellent outcomes and decreasing transplant related mortality (TRM) over time." | ( Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Gonsalves, WI; Hayman, SR; Hogan, WJ; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; Leung, N; Muchtar, E; Sidana, S; Sidiqi, MH; Warsame, R; Wolf, RC, 2019) |
| "Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy." | ( Cheesman, S; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Manwani, R; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Smith, M; Wechalekar, AD; Worthington, S; Yong, K, 2019) |
| "In this study, 94 patients with AL amyloidosis (baseline BNP ≥150 pg/ml) had BNP measured at 6 months following treatment." | ( Doros, G; Lilleness, B; Ruberg, FL; Sanchorawala, V, 2020) |
| "Patients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects." | ( Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J, 2021) |
| "The goal of therapy in AL amyloidosis is to inhibit further production of the amyloidogenic light chains, thereby allowing organ recovery and improving survival." | ( Al Saleh, AS; Buadi, F; Dingli, D; Dispenzieri, A; Gertz, M; Gonsalves, W; Hayman, S; Hogan, W; Kourelis, T; Kumar, S; Lacy, M; Leung, N; Muchtar, E; Sidiqi, MH; Vaxman, I; Warsame, R, 2021) |
| "We conducted a retrospective study of AL amyloidosis patients treated with bortezomib to investigate the predictive value of a stringent dFLC response." | ( Cao, XX; Feng, J; Li, J; Miao, HL; Shen, KN; Wei, S; Zhang, CL; Zhang, L; Zhou, DB, 2021) |
| "Newly diagnosed patients with AL amyloidosis treated with ASCT or bortezomib between 2001 and 2018 were identified." | ( Cohen, O; Fontana, M; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Mahmood, S; Manwani, R; Martinez De Azcona Naharro, A; Petrie, A; Sachchithanantham, S; Sharpley, FA; Wechalekar, AD; Whelan, CJ, 2021) |
| "All patients seen at the National Amyloidosis Centre, UK, between February 2010 and August 2019 and treated with up-front bortezomib are included." | ( Cohen, OC; Foard, D; Fontana, M; Gillmore, JD; Hawkins, PN; Lachmann, HJ; Law, S; Mahmood, S; Martinez-Naharro, A; Ravichandran, S; Sachchithanantham, S; Wechalekar, AD; Whelan, C, 2021) |
| "We review the management of AL amyloidosis, including factors that determine transplant eligibility, treatment options for transplant-ineligible patients, and treatment options for relapsed/refractory AL amyloidosis." | ( Abdallah, M; Sanchorawala, V, 2022) |
| "Strikingly, in mice bearing AL amyloidosis cell line xenografts, single agent treatment with the BCL-2 inhibitor ABT-199 (venetoclax) produces deeper remissions than bortezomib and triples median survival." | ( Blevins, F; Bradshaw, GA; Choiniere, J; Fraser, CS; Hata, AN; Kalocsay, M; Li, C; Miller, JW; Presser, A; Qin, X; Sanchorawala, V; Sarosiek, KA; Sarosiek, S; Spetz, JKE; Yu, S, 2022) |
| "We collected medical records of 302 AL amyloidosis patients and compared survival outcomes by predominant treatment strategy and at four time points: 1995-2003, 2004-2008, 2009-2013, and 2014-2018." | ( Choi, JO; Choi, JY; Jeon, ES; Kim, BJ; Kim, D; Kim, JS; Kim, K; Kim, SJ; Lee, JE; Min, JH; Yoon, SE, 2023) |
| "Herein we report a case of AL amyloidosis who was treated with HDM-ASCT, resulting in preserved cardiac function and resolution of proteinuria for more than 17 years after HDM-ASCT ensuing atrial fibrillation and complete atrioventricular block required management by catheter ablation and pacemaker implantation 10 years and 12 years after transplantation, respectively." | ( Iijima, T; Ikuma, D; Kono, K; Mizuno, H; Oba, Y; Ohashi, K; Sawa, N; Suwabe, T; Ubara, Y; Wake, A; Yamanouchi, M, 2023) |
| "In untreated systemic AL amyloidosis, Dara-Vd produces rapid and deep hematologic and organ responses." | ( Aras, MA; Arora, S; Chung, A; Kennedy, VE; Maringanti, SA; Martin, TG; Natsuhara, K; Shah, ND; Wolf, J; Wong, SW, 2023) |